|
|
Volumn 2, Issue 4, 2008, Pages 349-360
|
|
Predictive tests for individualization of pharmacological cancer treatment
a
|
|
Author keywords
Cancer drug; Cancer treatment; Individualization; Predictive test; Prognostic factor
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANTIESTROGEN;
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
CETUXIMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ERLOTINIB;
ESTROGEN RECEPTOR;
GEFITINIB;
IMATINIB;
PANITUMUMAB;
PLATINUM DERIVATIVE;
PROTEIN TYROSINE KINASE INHIBITOR;
RITUXIMAB;
TAMOXIFEN;
TRASTUZUMAB;
ADJUVANT THERAPY;
BREAST CANCER;
CANCER DIAGNOSIS;
CANCER STAGING;
CANCER THERAPY;
CHRONIC MYELOID LEUKEMIA;
CLINICAL EFFECTIVENESS;
CLINICAL TRIAL;
COLORECTAL CANCER;
COMBINATION CHEMOTHERAPY;
DRUG ACTIVITY;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG SENSITIVITY;
DRUG TARGETING;
GASTROINTESTINAL STROMAL TUMOR;
GENE EXPRESSION REGULATION;
GENOMICS;
HUMAN;
INDIVIDUALIZATION;
LABORATORY TEST;
MONOTHERAPY;
NONHODGKIN LYMPHOMA;
OVARY CANCER;
PREDICTION;
PROGNOSIS;
PROTEIN EXPRESSION;
PROTEOMICS;
REVIEW;
SIGNAL TRANSDUCTION;
TUMOR CELL;
VALIDATION PROCESS;
|
|
EID: 67749139054
PISSN: 17530059
EISSN: 17530067
Source Type: Journal
DOI: 10.1517/17530059.2.4.349 Document Type: Review |
|
Times cited : (12)
|
|
References (78)
|
